How Does the COVID-19 Antiviral Medications Workflow Compare to the Traditional Antiviral Production Pipeline

 

As the COVID-19 pandemic continues to progress researchers and scientists are starting to learn more about the virus in order to effectively combat it. One of those lessons is how the COVID-19 virus compares to other viruses when it comes to developing treatments. Justin Honore talked to Dr. Kishor Wasan, PH.D.,FAAPS, FCAHS, FCSPS, Chief Medical & Scientific Officer at Skymount Medical and a Distinguished University Scholar Adjunct Professor at the University of British Columbia about how COVID-19 vaccine research and production compare to the traditional antiviral and antibiotic production pipeline.

Follow us on social media for the latest updates in B2B!

Latest

The Challenges of Working Capital for Small and Mid-Size Construction Businesses
September 23, 2022
Record inflation, rising interest rates, and myriad supply chain issues are an amalgamation of challenges for any business in today’s climate. For small and mid-size construction companies, any of these issues Read more
Bluedot’s Report Offers Restaurants Insight Into Consumer Spending Behaviors
September 23, 2022
Inflation and ongoing concerns of a recession are affecting consumer spending behaviors. And as always, the restaurant industry is a great place to take the temperature of what people are willing to Read more
Advancements in Bone Health Imaging with Dr. Ego Seeman
September 23, 2022
  CurveBeam AI Medical Director - Endocrinology Prof. Ego Seeman recently sat down with Vinti Singh, CurveBeam AI’s Marketing Director, to discuss the future of bone health imaging. Prof. Seeman is a Read more